This study is testing a new medicine, **redasemtide**, for adults who've had an **acute ischemic stroke (AIS)**. AIS happens when a blood clot blocks blood flow to the brain. The study aims to see how well redasemtide works and if it's safe. To join, you must start the study treatment within 25 hours after the stroke. You should not need other treatments like **thrombolysis** (a medicine that breaks clots) or **mechanical thrombectomy** (a procedure to remove clots). Your starting **NIHSS** score, which measures stroke severity, should be between 8 and 22. Some conditions, such as a recent severe heart problem or very high blood pressure, can prevent participation. The study will observe your health and recovery process.

• Participation in the study should not require hospitalization during the follow-up period.
• Redasemtide is not for people who've had redasemtide or investigational products in the past 90 days.
• Participants must not have severe neurological conditions or very low/high blood sugar.